APA-referens

Mao, Y., Xi, L., Li, Q., Wang, S., Cai, Z., Zhang, X., & Yu, C. (2018). Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma. Transl Oncol.

Chicago-stil citat

Mao, Yonghuan, Ling Xi, Quan Li, Sheng Wang, Zeling Cai, Xinhua Zhang, och Chunzhao Yu. "Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma." Transl Oncol 2018.

MLA-referens

Mao, Yonghuan, et al. "Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma." Transl Oncol 2018.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.